Epidemiology of APO- and Lipoproteins in Elderly Women

This study has been completed.
Sponsor:
Information provided by:
National Heart, Lung, and Blood Institute (NHLBI)
ClinicalTrials.gov Identifier:
NCT00005223
First received: May 25, 2000
Last updated: June 23, 2005
Last verified: April 2001
  Purpose

To examine the complex interactions among the traditional cardiovascular risk factors, particularly lipoprotein and apoprotein levels, genetic and other characteristics, and lifestyle habits in elderly women.


Condition
Cardiovascular Diseases
Heart Diseases
Coronary Disease

Study Type: Observational

Resource links provided by NLM:


Further study details as provided by National Heart, Lung, and Blood Institute (NHLBI):

Study Start Date: April 1988
Estimated Study Completion Date: March 1993
Detailed Description:

BACKGROUND:

Coronary heart disease is the leading cause of death in both men and women 65 years of age and older, and in 1982, it was estimated that it accounted for about 32.4 percent of all deaths in this age group and may have contributed to death in an additional 12.1 percent. Coronary heart disease mortality rates increase steeply with age, even in those over 65 years of age. Death rates for males continue to be higher than females although the sex ratio declined sharply with age. Data from Framingham suggest that although the incidence of coronary heart disease rises with age in both males and females, the incidence rate rises more steeply in elderly females compared with elderly males. Despite the magnitude of this problem, in 1988 the majority of the knowledge on coronary heart disease and its risk factors related to the disease in middle-aged persons--primarily males. More information was needed about coronary heart disease and its risk factors in elderly women. Also, the atherosclerotic process develops over many years and the risk factors which relate to the evolution of atherosclerosis are highly correlated within an individual. Therefore, it is likely that risk factors, such as lipoproteins and apoproteins will be important determinants of coronary heart disease in older persons primarily because of this observed correlation within individuals over time, and their long-term association with the development and progression of atherosclerosis. In addition, identification of the high risk individual is a goal of many epidemiologic investigations. It is possible that qualitative examination of the polymorphisms of the apoproteins could in fact assist in the identification of women at high risk of coronary heart disease who are in need of aggressive prophylaxis. These genetic markers represent a second generation of risk factors for coronary heart disease.

DESIGN NARRATIVE:

The study was ancillary to the multicenter Study of Osteoporotic Fractures (SOF), a prospective study on risk factors for hip and wrist fractures supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases. The cross-sectional study involved a sample of subjects at the Pittsburgh Center. The distribution and interrelationships of lipoproteins and apoproteins were described as were their relationships to age, years since menopause, type of menopause, and lifestyle factors such as physical activity, alcohol consumption, cigarette smoking, obesity, and use of estrogens/progestins. The frequency of phenotypes of the polymorphisms of apoprotein A-IV and E were examined to determine whether these phenotypes were associated with specific patterns of lipo- and apoproteins. The hypothesis was tested that the degree to which lifestyle characteristics explain the variability in lipoproteins and apoproteins depended on the genetic makeup of the individual.

  Eligibility

Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

No eligibility criteria

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

Publications:

ClinicalTrials.gov Identifier: NCT00005223     History of Changes
Other Study ID Numbers: 1102
Study First Received: May 25, 2000
Last Updated: June 23, 2005
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Cardiovascular Diseases
Coronary Disease
Coronary Artery Disease
Heart Diseases
Myocardial Ischemia
Vascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases

ClinicalTrials.gov processed this record on August 28, 2014